Greg Post Since its discovery in the late 1950’s Coenzyme Q10 (CoQ10) has received untold attention as a necessary compound for proper cellular function. It is the essential coenzyme needed for the production of ATP (adenosine triphosphate) upon which all cellular functions depend. Without ATP our bodies cannot function properly. Without CoQ10, ATP cannot function. This connection has made CoQ10 a very influential object of study in relation to chronic disease. In many cases the presence of degenerative disease is related with inadequate levels of CoQ10. But no area of study has acceptable more attention than the relation between CoQ10 and heart disease. That is because CoQ10 is believed to be of fundamental importance in cells with high metabolic demands such as cardiac cells. A far reason the connection of heart disease and CoQ10 has gained so untold attention is because heart conditions of many kinds are associated with chronically low CoQ10 levels. CoQ10 is highly concentrated in heart muscle cells because of their higher energy requirements. Add this to the fact that heart disease is the number one killer in developed and developing countries and one can see why the bulk of scientific research on CoQ10 has been concerned with heart disease. Specifically, studies on congestive heart failure have demonstrated a brawny correlation between the severity of heart failure and the degree of CoQ10 deficiency. The lower the levels of CoQ10 in the heart muscles the more severe the heart failure. If indeed CoQ10 deficiency is a direct cause of congestive heart failure then, in such cases, the remedy is simple and cost effective; CoQ10 supplementation. Congestive heart failure is a condition where the heart does not pump effectively subsequent in an accumulation of fluid in the lungs. Symptoms may include shortness of breath, difficulty breathing when untruthful flat and leg or ankle swelling. Causes include degenerative hypertension, cardiomyopathy (primary heart disease) and myocardial infarction (irreversible injury to heart muscles). Heart muscle strength is measure by the ejection fraction which is a measure of the fraction of blood pumped down of the heart with each beat. A low ejection fraction indicates a weak heart. Several trials have been conducted involving patients with increased weak heart muscles of unknown causes. For those of you who same difficult phrases this condition (or variety of conditions) is known as idiopathic dilated cardiomyopathy. In these trials CoQ10 supplementation was compared to placebo effects. Standard treatments for heart failure were not discontinued. The results were plumbed by echocardiography (a diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures). The overall results of CoQ10 supplementation incontestable a steady and continued improvement in heart function as well as resolute and continued reduction in patient symptoms including fatigue, chest pains, palpitations and breathing difficulty. Patients with more establish and long-term cases showed gradual improvement but did not gain normal heart function. Patients with newer cases of heart failure incontestable much more fast improvement often regressive to normal heart function. Papers numbering in the hundreds from eight different symposia have been transcribed and presented on the effects of CoQ10 on heart disease. International objective studies have also been conducted in the United States, Japan, Germany, Italy and Sweden. unneurotic these studies and the papers that have been plagiarised from them demonstrate significant improvement in heart muscle function while causing no adverse effects. One specific area of study involves diastolic dysfunction which is cardinal of the early signs of myocardial failure. Diastole is the phase of the cardiac cycle when the heart is filled with returning blood. Because this phase requires more cellular energy than the systolic phase (when the blood is pushed out of the heart) it is more dependent on CoQ10. Diastolic dysfunction is a stiffening of the heart muscle which naturally restricts the heart’s ability to pump. This condition is associated with galore cardiac disorders. Hypertension is among these disorders. As the heart muscles become stiff there is often a commensurate rise in blood pressure. When the diastolic dysfunction is reversed, blood pressure tends to lower as well. In one study involving 109 patients with hypertension, CoQ10 supplementation was added to normal hypertension treatments. In an normal of 4.4 months 51% of the patients were competent stop using at least one blood pressure lowering medication. Some were competent to stop using up to cardinal medications. Another study produced similar results. In that study 43% of 424 patients were competent to stop using between one and three cardiovascular drugs because of CoQ10 supplementation. These examples are retributory a drop in the bucket. Diastolic dysfunction (and by proxy, hypertension) includes only a miniscule sampling of heart conditions that respond favorably to CoQ10 supplementation. Other areas of research show great promise for CoQ10 treatments. Among these are cancer and AIDS. But such conditions are beyond the scope of this essay. CoQ10 is unexpendable to the prissy functioning of complete cell types. It is not surprising, therefore, to find a diverse number of diseases that respond favorably to CoQ10 supplementation. Since all metabolically nimble tissues are highly sensitive to CoQ10 deficiency, we can expect to see CoQ10 research expand to many opposite areas of degenerative diseases. About The Author

Greg Post Throughout my childhood I was aware of the importance of eating well and taking my vitamins. But the science of dietary supplements has come a long way since those days. And one of the stars in this scientific progression is Coenzyme Q10 (CoQ10). CoQ10 is not a drug. It is a vitamin-like substance that is found in miniscule amounts in a variety of foods and is synthesized within our body tissues. Enzymes are compounds in the body that are absolutely unexpendable for the galore processes necessary to keep us liveborn and our bodies functioning properly. Mitochondrial enzymes are those particular enzymes that are essential for the production of the high-energy phosphate ATP (adenosine triphosphate) upon which complete cellular function depends. Without it our bodies shut falling at the alveolate level. Coenzyme Q10 is the cofactor upon which at least three mitochondrial enzymes depend. By logical inference past ATP functioning depends upon CoQ10. In short, all hominian cellular function depends on ATP. And ATP function depends on CoQ10. As was already said, the production of CoQ10 occurs within our body tissues. Its biosynthesis from the amino unpleasant tyrosine is a complex multistage process requiring several vitamins and trace elements. Under normal conditions we produce complete we need while we are young. But there are many factors that can contribute to CoQ10 deficiency. Among these are aging, disease, dietary deficiency, use of statin drugs and incorporative tissue demands. Before we get to CoQ10 deficiencies, however, it is healed to look at the history of CoQ10 research. History CoQ10 was archetypical isolated by Dr. Frederick Crane in 1957 from the mitochondria of beef heart. During that same year Professor Morton, from Britain, also discovered CoQ10 in the livers of vitamin A deficient rats. During the following year researchers at Merck, Inc. determined its chemical structure and became the archetypical to produce it. It was neither the British nor the Americans that first saved a practical use for the CoQ compounds. Professor Yamamura from Japan archetypical used a incidental to compound (CoQ7) in the treatment of congestive heart failure. Other practical uses then followed. CoQ6 was used as an effective antioxidant in the middle 1960s. In 1972 (in Italy) deficiency of CoQ10 was linked to heart disease. The Japanese, however, were the first to flawless the technology needed to produce CoQ10 in sizeable sufficient quantities to make large clinical trials a reality. After Peter Mitchell won the Nobel Prize in 1978 for defining the biological energy transfer that occurs at the cellular equal (for which CoQ10 is essential) there was a large increase in the number of objective studies performed in relation to CoQ10 usefulness. This was due in part to the life-sized amounts of pharmaceutical grade CoQ10 that was now acquirable from Japan and the ability to measure CoQ10 in blood and body tissues. CoQ10 since has become celebrated for its importance as a stiff antioxidant and liberated radical scavenger and as a treatment in many degenerative illnesses, especially heart disease. Coenzyme Q10 Deficiency The usefulness of CoQ10 as a medical treatment has largely been approached from the perspective that when a degenerative disease is attending (especially in the case of heart disease) CoQ10 is often grossly deficient. For example, a person suffering from congestive heart failure often demonstrates intense CoQ10 deficiency. mean blood and tissue levels of CoQ10 have been healed established. Significantly contrabass levels of CoQ10 have been connected to a big variety of diseases in both mammal-like and human studies. But if CoQ10 is biosynthesized in our bodies why do we often suffer from deficiency? There are at least cardinal causes. The archetypical is an stingy diet. Dietary intake of CoQ10 is an important factor in total blood and tissue levels of the compound. If we do not consume sufficient of the foods that contain CoQ10 then the body must make up the difference. Further, the biosynthesis of Coenzyme Q10 is a complex 17-step process involving a whole string of B vitamins, vitamin C and pantothenic acid. Diets inadequate in these compounds make CoQ10 synthesis impossible. This is not the place to discuss the condition of the average diet and the vitamin inadequate nature of galore of our food sources. Suffice it to say that most of us do not get nearly enough CoQ10 or the opposite vitamins necessary for optimal synthesis. The second cause of deficiency is linked to the first, and that is impairment of CoQ10 biosynthesis. In addition to deficient intakes of the compounds necessary to make CoQ10 there are other begotten reasons for deficient production of it. These might include physiological conditions and chronic diseases that cause failure in production. The treatments of diseases can also be a factor. For instance the use of statins to control cholesterol levels has been implicated in the depletion of CoQ10 levels. The catch-22 is, in treating heart disease we use drugs that deplete earthy compounds that in turn are needed to fight heart disease. The third cause of CoQ10 deficiency is excessive use of the compound by the body. This again can be related to medications, aging or opposite causes such as excessive exertion, hypermetabolism, and acute shock states. The realistic cause of CoQ10 deficiency is usually a combination of these three influences. It is promising that the normal CoQ10 levels which have been determined in humans are suboptimal. In opposite words, the mean levels of CoQ10 that have become the standard for comparisons are precise likely less than optimal. That would mean that the extremely low levels observed in connection with chronic diseases are just the worse case scenarios and that opposite less serious maladies are connected with lesser levels of deficiency. If this sounds too much like laboratory theory, it isn’t. Patients who suffer from chronic diseases and also demonstrate extreme low levels of CoQ10 are not laboratory specimens. They are people who, in galore cases, have been greatly helped by CoQ10 supplementation. If chronic disease is only the tip of the iceberg when it comes to CoQ10 deficiency one is involuntary to wonder what better diets and CoQ10 supplementing could do for the eradication of diseases and other degenerative conditions. About The Author

Greg Post Since the 1960’s there have been many controlled clinical trials concerning the relationship between congestive heart failure and Coenzyme Q10 (CoQ10). As its name implies CoQ10 is a coenzyme that is necessary for the proper functioning of other substances, cardinal of the most important of which is ATP (adenosine triphosphate). ATP is necessary for the production of alveolate energy. By proxy CoQ10 is likewise essential for this process. Clinical trials have unsuccessful to study the relationship between CoQ10 and many degenerative diseases including, but not limited to, heart disease, cancer and AIDS. But heart disease has gained the most attention; congestive heart failure being cardinal of the direct subjects. Because heart muscle cells require so much energy to function and CoQ10 is at the core of the cellular energy process it makes sense to questionable that congestive heart failure might be linked to CoQ10 deficiency. With that theory in mind many studies same the ones that follow have been conducted. These trials have been given in this essay in thumbnail format. One early Japanese trial (1972) concerned 197 patients with varying levels of severity of cardiac failure. The study reported significant improvement of cardiac function supplementing with 30 mg per day of CoQ10. other Japanese study incontestable similar results with 38 patients also supplementing with 30 mg. In 1985 a U.S. objective study prescribed regular supplementation with cardinal mg of the coenzyme for treatment periods of cardinal months for patients with low ejection fraction measurements. The ejection fraction is the measure of the heart’s ability to pump blood. A low ejection fraction is a classic symptom of congestive heart failure. Again, significant improvements in heart function were reported. opposite clinical trials followed prescribing the unvarying level of supplementation with similar results. Studies in the early 1990s showed improvement for patients suffering from ischemic cardiomyopathy (a low oxygen state usually due to obstruction) with secondary levels of cardinal mg per day. Supplementing with cardinal mg per day demonstrated improvement for patients suffering from idiopathic dilated cardiomyopathy, an enlarged heart syndrome of unidentified cause. One of the largest trials of the 1990s involves 641 patients randomly segmented into two groups. The first group received a placebo. The other group received CoQ10 supplements. During the one-year follow-up period 118 patients in the placebo group were hospitalized for heart failure compared to 73 in the group that acceptable the supplements. All of the preceding trials were relatively short-term studies. The level of improvement among patients varied depending on how long they had been troubled from some aspect of congestive heart failure. Through the years it has become increasing broad that the superior improvements were shown in patients that had suffered from their condition the least amount of time. In opposite words, the longer a person had been suffering from the disease before he or she received CoQ10 treatments the less improvement was demonstrated. People who had acceptable treatments early in the development of the disease showed the most melodramatic improvement often regressive to normal heart function. Long-term sufferers received less relief and were little likely to return to full heart function. Whatever the reasons for this disparity in health improvement, it demonstrates the importance of receiving treatment as early as possible. But what active long-term studies? Do they show the same marked improvement with similar treatment? In the short trials it was apparent that equal high level supplementing with CoQ10 seemed to produce no ill effects. In order to determine if this is only true for short durations a number of long studies were conducted. In 1990 observations were published concerning 126 patients with dilated cardiomyopathy. Unlike previously noted studies this one followed the patients’ progress for six years. Long-term benefits from CoQ10 supplementing were noticed with no harmful side effects. Similar observations were made in a trial involving 2,664 patients treated with CoQ10 at levels up to cardinal mg per day. A 1994 study involving 424 patients with a variety of myocardial (refers to the heart's muscle mass) diseases. Among these conditions were the following: Valvular heart disease (pertaining to dysfunction of heart valves), hypertension, diastolic dysfunction (failure of the heart to properly refill itself with blood), expanded cardiomyopathy (group of disorders where the heart muscle is weakened and increased and cannot pump effectively) and ischemic cardiomyopathy (low oxygen state usually repayable to obstruction of the arterial blood supply). Patients were treated with an average of 240 mg of CoQ10 daily during their treatment period. They were then followed-up for up to eight years with an average follow-up period of 18 months. Overall results demonstrated measurable cardiac improvements in cardinal month with supreme improvements at active six months. With continued CoQ10 treatment the improvement in most patients was sustained. However, discontinuing the treatment usually resulted in a decline of cardiac function with ultimate return to pre-treatment conditions. As always in the medical community galore more studies will need to be conducted to determine the future of CoQ10 treatment. However, the research to date seems to support CoQ10 as a viable treatment for many diseases that are caused or exacerbated by inadequate production of cellular energy. About The Author